199807-35-7 | CILENGITIDE TRIFLUOROACETATE

Packsize	Purity	Availability	Price	Discounted Price
1mg	99%	in stock	$39.00	$27.00
5mg	99%	in stock	$76.00	$53.00

Description

• Catalog Number: AF37945
• Chemical Name: CILENGITIDE TRIFLUOROACETATE
• CAS Number: 199807-35-7
• Molecular Formula: C29H41F3N8O9
• Molecular Weight: 702.6792496000003
• MDL Number: MFCD22665738
• SMILES: OC(=O)C(F)(F)F.OC(=O)C[C@@H]1NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N(C(=O)[C@H](NC1=O)Cc1ccccc1)C)C(C)C

Computed Properties

• Complexity: 1110
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 49
• Hydrogen Bond Acceptor Count: 13
• Hydrogen Bond Donor Count: 8
• Rotatable Bond Count: 9

Literature

• Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.

  Oncotarget 20160322

• Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

  The Lancet. Oncology 20140901

• Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.

  Anticancer research 20121001

• Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature.

  Anti-cancer drugs 20120801

• A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.

  Melanoma research 20120801

• A phase I study of continuous infusion cilengitide in patients with solid tumors.

  Investigational new drugs 20120401

• Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.

  Investigational new drugs 20120401

• Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.

  Journal of neuro-oncology 20120101

• Cilengitide treatment for malignant glioma: current status and future direction.

  Neurologia medico-chirurgica 20120101

• Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.

  Investigational new drugs 20111201

• Cilengitide inhibits metastatic bone colonization in a nude rat model.

  Oncology reports 20111001

• [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].

  Bulletin du cancer 20111001

• Increasing αvβ3 selectivity of the anti-angiogenic drug cilengitide by N-methylation.

  Angewandte Chemie (International ed. in English) 20110926

• Cilengitide induces autophagy-mediated cell death in glioma cells.

  Neuro-oncology 20110801

• Radiation-induced modifications of the tumor microenvironment promote metastasis.

  Bulletin du cancer 20110601

• Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study.

  International journal of cancer 20110515

• Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.

  Future oncology (London, England) 20110301

• Angiogenesis and invasion in glioma.

  Brain tumor pathology 20110201

• Evaluation of treatment response of cilengitide in an experimental model of breast cancer bone metastasis using dynamic PET with 18F-FDG.

  Hellenic journal of nuclear medicine 20110101

• What role should cilengitide have in the treatment of glioblastoma?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101120

• [Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].

  Der Nervenarzt 20100801

• Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100601

• Integrins as target: first phase III trial launches, but questions remain.

  Journal of the National Cancer Institute 20100519

• Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100415

• Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.

  Neuro-oncology 20091201

• Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis.

  Hepatology (Baltimore, Md.) 20091101

• Small molecule integrin antagonists in cancer therapy.

  Mini reviews in medicinal chemistry 20091001

• Will integrin inhibitors have proangiogenic effects in the clinic?

  Nature medicine 20090701

• Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.

  International journal of cancer 20090601

• Cilengitide: does it really represent a new targeted therapy for recurrent glioblastoma?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090410

• The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.

  PloS one 20090101

• Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081201

• Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.

  Expert opinion on investigational drugs 20080801

• The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.

  Oncology reports 20080401

• Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080220

• [Cilengitide: a new weapon against glioblastoma?].

  Tumori 20080101

• Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.

  Journal of experimental & clinical cancer research : CR 20080101

• American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 4.

  IDrugs : the investigational drugs journal 20070801

• Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070801

• Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro.

  Biochemical and biophysical research communications 20070615

• Integrin inhibitors reaching the clinic.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501

• Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501

• Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice.

  Neurosurgery 20061201

• Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.

  Anti-cancer agents in medicinal chemistry 20060901

• Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.

  International journal of radiation oncology, biology, physics 20060801

• [Advances in the study of the integrin alpha(v) beta3 antagonists].

  Yao xue xue bao = Acta pharmaceutica Sinica 20060701

• Integrins: molecular targets in cancer therapy.

  Current oncology reports 20060301

• Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.

  Clinical genitourinary cancer 20060301

• A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.

  BMC cancer 20060101

• Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.

  Journal of medicinal chemistry 20051201

• [Inhibition of cellular adhesion and invasion in gliomas].

  Nihon rinsho. Japanese journal of clinical medicine 20050901

• Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.

  Oncology (Williston Park, N.Y.) 20041201

• Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour.

  Oral oncology 20040201

• Cilengitide Merck.

  Current opinion in investigational drugs (London, England : 2000) 20030601

• Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.

  European journal of cancer (Oxford, England : 1990) 20030501

• alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.

  Angiogenesis 20030101

• Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.

  Cancer research 20020801

• Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand.

  Science (New York, N.Y.) 20020405

• Snake venom protein paralyzes cancer cells.

  Journal of the National Cancer Institute 20010221

• Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist.

  Neurosurgery 20010101